1-Deamino-8-D-arginine vasopressin (DDAVP) increases platelet membrane expression of glycoprotein Ib in patients with disorders of platelet function and after cardiopulmonary bypass.

Sloand EM, Alyono D, Klein HG, Chang P, Yu M, Lightfoot FG, Kessler C

American journal of hematology1 Jul 1994Cited by 24 (Europe PMC)

PMID8192149DOI10.1002/ajh.2830460308PepBankPUB-08192149

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanNon-randomized trialMechanism
In bypass patients, platelet CD42b antibody binding increased more with DDAVP than without DDAVP during 18-20 hours after surgery.
In plain wordsAfter bypass surgery, DDAVP increased platelet CD42b antibody binding more than no DDAVP.
Peptide
Desmopressin
Outcome
IncreaseCD42b antibody binding after bypass
Study
n = 22
Comparator
Patients not receiving DDAVP
Outcome group
Bleeding and clotting · Cardiovascular
Studied dose
0.3 microgram/kg · infusionAs given in this study (human).
Source sentences
Summary
Binding of CD42b monoclonal antibody (MoAb) and anti-GPIb/IX to platelets from both groups of bypass patients increased during the 18-20 hr after surgery, but the group receiving DDAVP showed the greater increase (P = 0.032).
2 context sentences(design, population, supporting numbers)
Summary · context
Platelets from 8 cardiopulmonary bypass patients, receiving DDAVP immediately after surgery, were compared to those of 14 patients not receiving DDAVP.
Summary · context
We studied platelet membrane glycoproteins in patients with von Willebrand disease (vWD), disorders of platelet function, and in cardiopulmonary bypass patients after infusion of 0.3 microgram/kg of DDAVP.
Report a problemFND-0819214901
02HumanNon-randomized trialMechanism
In bypass patients, platelet anti-GPIb/IX binding increased more with DDAVP than without DDAVP during 18-20 hours after surgery.
In plain wordsAfter bypass surgery, DDAVP increased platelet anti-GPIb/IX binding more than no DDAVP.
Peptide
Desmopressin
Outcome
IncreaseAnti-GPIb/IX binding after bypass
Study
n = 22
Comparator
Patients not receiving DDAVP
Outcome group
Bleeding and clotting · Cardiovascular
Studied dose
0.3 microgram/kg · infusionAs given in this study (human).
Source sentences
Summary
Binding of CD42b monoclonal antibody (MoAb) and anti-GPIb/IX to platelets from both groups of bypass patients increased during the 18-20 hr after surgery, but the group receiving DDAVP showed the greater increase (P = 0.032).
2 context sentences(design, population, supporting numbers)
Summary · context
Platelets from 8 cardiopulmonary bypass patients, receiving DDAVP immediately after surgery, were compared to those of 14 patients not receiving DDAVP.
Summary · context
We studied platelet membrane glycoproteins in patients with von Willebrand disease (vWD), disorders of platelet function, and in cardiopulmonary bypass patients after infusion of 0.3 microgram/kg of DDAVP.
Report a problemFND-0819214902
03HumanNon-randomized trialMechanism
In patients with von Willebrand disease, DDAVP increased platelet CD42b antibody binding.
In plain wordsIn patients with von Willebrand disease, DDAVP increased platelet CD42b antibody binding.
Peptide
Desmopressin
Outcome
IncreaseCD42b antibody binding in vWD
Study
n = 12
Outcome group
Bleeding and clotting · Cardiovascular
Studied dose
0.3 microgram/kg · infusionAs given in this study (human).
Source sentences
Summary
Platelets from patients receiving DDAVP for vWD or for platelet dysfunction, had increases in CD42b MoAb and anti-GPIb/IX binding (P < 0.01) that coincided with shortening of their bleeding time.
2 context sentences(design, population, supporting numbers)
Summary · context
We also studied 12 patients with vWD, and 8 patients with platelet dysfunction receiving DDAVP.
Summary · context
We studied platelet membrane glycoproteins in patients with von Willebrand disease (vWD), disorders of platelet function, and in cardiopulmonary bypass patients after infusion of 0.3 microgram/kg of DDAVP.
Report a problemFND-0819214903
04HumanNon-randomized trialMechanism
In patients with von Willebrand disease, DDAVP increased platelet anti-GPIb/IX binding.
In plain wordsIn patients with von Willebrand disease, DDAVP increased platelet anti-GPIb/IX binding.
Peptide
Desmopressin
Outcome
IncreaseAnti-GPIb/IX binding in vWD
Study
n = 12
Outcome group
Bleeding and clotting · Cardiovascular
Studied dose
0.3 microgram/kg · infusionAs given in this study (human).
Source sentences
Summary
Platelets from patients receiving DDAVP for vWD or for platelet dysfunction, had increases in CD42b MoAb and anti-GPIb/IX binding (P < 0.01) that coincided with shortening of their bleeding time.
2 context sentences(design, population, supporting numbers)
Summary · context
We also studied 12 patients with vWD, and 8 patients with platelet dysfunction receiving DDAVP.
Summary · context
We studied platelet membrane glycoproteins in patients with von Willebrand disease (vWD), disorders of platelet function, and in cardiopulmonary bypass patients after infusion of 0.3 microgram/kg of DDAVP.
Report a problemFND-0819214904
05HumanNon-randomized trialEfficacy outcome
In patients with von Willebrand disease, DDAVP shortened bleeding time alongside increased platelet antibody binding.
In plain wordsIn patients with von Willebrand disease, DDAVP shortened bleeding time.
Peptide
Desmopressin
Outcome
DecreaseBleeding time in vWD
Study
n = 12
Outcome group
Bleeding and clotting · Cardiovascular
Studied dose
0.3 microgram/kg · infusionAs given in this study (human).
Source sentences
Summary
Platelets from patients receiving DDAVP for vWD or for platelet dysfunction, had increases in CD42b MoAb and anti-GPIb/IX binding (P < 0.01) that coincided with shortening of their bleeding time.
2 context sentences(design, population, supporting numbers)
Summary · context
We also studied 12 patients with vWD, and 8 patients with platelet dysfunction receiving DDAVP.
Summary · context
We studied platelet membrane glycoproteins in patients with von Willebrand disease (vWD), disorders of platelet function, and in cardiopulmonary bypass patients after infusion of 0.3 microgram/kg of DDAVP.
Report a problemFND-0819214905
06HumanNon-randomized trialMechanism
In patients with platelet dysfunction, DDAVP increased platelet CD42b antibody binding.
In plain wordsIn patients with platelet dysfunction, DDAVP increased platelet CD42b antibody binding.
Peptide
Desmopressin
Outcome
IncreaseCD42b antibody binding in platelet dysfunction
Study
n = 8
Outcome group
Bleeding and clotting · Cardiovascular
Studied dose
0.3 microgram/kg · infusionAs given in this study (human).
Source sentences
Summary
Platelets from patients receiving DDAVP for vWD or for platelet dysfunction, had increases in CD42b MoAb and anti-GPIb/IX binding (P < 0.01) that coincided with shortening of their bleeding time.
2 context sentences(design, population, supporting numbers)
Summary · context
We also studied 12 patients with vWD, and 8 patients with platelet dysfunction receiving DDAVP.
Summary · context
We studied platelet membrane glycoproteins in patients with von Willebrand disease (vWD), disorders of platelet function, and in cardiopulmonary bypass patients after infusion of 0.3 microgram/kg of DDAVP.
Report a problemFND-0819214906
07HumanNon-randomized trialMechanism
In patients with platelet dysfunction, DDAVP increased platelet anti-GPIb/IX binding.
In plain wordsIn patients with platelet dysfunction, DDAVP increased platelet anti-GPIb/IX binding.
Peptide
Desmopressin
Outcome
IncreaseAnti-GPIb/IX binding in platelet dysfunction
Study
n = 8
Outcome group
Bleeding and clotting · Cardiovascular
Studied dose
0.3 microgram/kg · infusionAs given in this study (human).
Source sentences
Summary
Platelets from patients receiving DDAVP for vWD or for platelet dysfunction, had increases in CD42b MoAb and anti-GPIb/IX binding (P < 0.01) that coincided with shortening of their bleeding time.
2 context sentences(design, population, supporting numbers)
Summary · context
We also studied 12 patients with vWD, and 8 patients with platelet dysfunction receiving DDAVP.
Summary · context
We studied platelet membrane glycoproteins in patients with von Willebrand disease (vWD), disorders of platelet function, and in cardiopulmonary bypass patients after infusion of 0.3 microgram/kg of DDAVP.
Report a problemFND-0819214907
08HumanNon-randomized trialEfficacy outcome
In patients with platelet dysfunction, DDAVP shortened bleeding time alongside increased platelet antibody binding.
In plain wordsIn patients with platelet dysfunction, DDAVP shortened bleeding time.
Peptide
Desmopressin
Outcome
DecreaseBleeding time in platelet dysfunction
Study
n = 8
Outcome group
Bleeding and clotting · Cardiovascular
Studied dose
0.3 microgram/kg · infusionAs given in this study (human).
Source sentences
Summary
Platelets from patients receiving DDAVP for vWD or for platelet dysfunction, had increases in CD42b MoAb and anti-GPIb/IX binding (P < 0.01) that coincided with shortening of their bleeding time.
2 context sentences(design, population, supporting numbers)
Summary · context
We also studied 12 patients with vWD, and 8 patients with platelet dysfunction receiving DDAVP.
Summary · context
We studied platelet membrane glycoproteins in patients with von Willebrand disease (vWD), disorders of platelet function, and in cardiopulmonary bypass patients after infusion of 0.3 microgram/kg of DDAVP.
Report a problemFND-0819214908
09HumanNon-randomized trialMechanism
In the studied patients, DDAVP did not change binding of the other platelet antibodies.
In plain wordsIn the studied patients, DDAVP did not change binding of the other platelet antibodies.
Peptide
Desmopressin
Outcome
No significant changeOther platelet antibody binding
Study
n: not reported in source
Outcome group
Bleeding and clotting · Cardiovascular
Studied dose
0.3 microgram/kg · infusionAs given in this study (human).
Source sentences
Summary
No changes were seen in binding of other antibodies.
2 context sentences(design, population, supporting numbers)
Summary · context
Fixed platelets, stained with monoclonal fluorescein (FITC)-labeled antibodies directed against GPIb (CD42b antigen), GPIb/IX, GPIIb/IIIa (CD41a antigen), CD63 antigen (a platelet activation protein), and P-selectin (CD62 antigen) were studied by flow cytometry.
Summary · context
We studied platelet membrane glycoproteins in patients with von Willebrand disease (vWD), disorders of platelet function, and in cardiopulmonary bypass patients after infusion of 0.3 microgram/kg of DDAVP.
Report a problemFND-0819214909

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.